FRED HURD BURBANK
Pilots at Old Rnch Rd, Laguna Beach, CA

6517498, Feb 11, 2003

Jul 20, 2000

09/619867

Fred H. Burbank - Laguna Niguel CA
William C. Homet - Capistrano Beach CA
Paul Lubock - Laguna Niguel CA

SenoRx, Inc. - Aliso Viejo CA

A61B 1000

600564, 600567, 606 45, 606170

A tissue acquisition system includes electrodes that are energized by a radio frequency (RF) energy source. Retractable electrodes are energized and extended from a cannula and the cannula is advanced in the tissue to position the cannula near the target tissue site in a patient. The retractable electrodes are then retracted and a distal electrode cuts a tissue sample from the tissue site when the cannula is further advanced into the tissue. The retractable electrodes are then energized and extended from the cannula and the cannula is rotated to separate the tissue sample from the tissue site. The tissue sample is ejected through the cannula for collection by advancing a dilator.

8224424, Jul 17, 2012

Jul 13, 2009

12/460052

Fred H. Burbank - Laguna Niguel CA, US
Paul Lubock - Laguna Niguel CA, US
Michael L. Jones - Capistrano Beach CA, US
Richard L. Quick - Mission Viejo CA, US
Frank Louw - Carlsbad CA, US
Stephen A. De Santis - Laguna Niguel CA, US

Senorx, Inc. - Irvine CA

A61B 5/00, A61B 6/00, A61B 19/00

600431, 600414, 600420, 600426, 600458

The invention is directed biopsy site markers and methods of marking a biopsy site, so that the location of the biopsy cavity is readily visible by conventional imaging methods, particularly by ultrasonic imaging. The biopsy site markers of the invention have high ultrasound reflectivity, presenting a substantial acoustic signature from a small marker, so as to avoid obscuring diagnostic tissue features in subsequent imaging studies, and can be readily distinguished from biological features. The several disclosed embodiments of the biopsy site marker of the invention have a high contrast of acoustic impedance as placed in a tissue site, so as to efficiently reflect and scatter ultrasonic energy, and preferably include gas-filled internal pores. The markers may have a non-uniform surface contour to enhance the acoustic signature. The markers have a characteristic form which is recognizably artificial during medical imaging.

2003012, Jun 26, 2003

Nov 19, 2002

10/300410

Fred Burbank - Laguna Niguel CA, US
Michael Jones - San Clemente CA, US
R. Serra - Irvine CA, US
Greig Altieri - Laguna Beach CA, US
Jill Uyeno - Mission Viejo CA, US
Yu-Tung Wong - Irvine CA, US
Randy Werneth - Poway CA, US

Vascular Control System

A61B017/10

606/142000

Medical devices, systems and methods for applying a luminal clip to occlude a body lumen, such as a blood vessel, duct, or lymph node are provided. Devices embodying features of the invention include an elongated pressure-applying member having a handle portion and a jaw portion with a clip-receiving surface; a sensor disposed on a jaw portion; and an energy transmission element connected to the sensor. The sensor may detect and/or locate a body lumen, and may be used to differentiate between a blood vessel and other body lumens. The device can apply a luminal clip to a body lumen to compress and to occlude the lumen. Occlusion may be partial or complete, and may be temporary or permanent. Occlusion of the uterine arteries may treat uterine fibroids, dysfunctional uterine bleeding, and other uterine disorders and conditions; clips may also be applied in cholecystectomy procedures, and in other medical procedures.

2008020, Aug 21, 2008

Apr 22, 2008

12/107652

Fred Burbank - Laguna Niguel CA, US
Greig E. Altieri - Laguna Beach CA, US
Michael L. Jones - Capistrano Beach CA, US

Vascular Control Systems, Inc. - San Juan Capistrano CA

A61B 17/42

606119

A method of treating a uterine disorder comprising non-permanently occluding a uterine artery with a resorbable embolic mass for a therapeutically effective time period. The occluding step includes selectively positioning the resorbable embolic mass within the uterine artery, and monitoring positioning of the resorbable embolic mass at a desired location within the uterine artery. The monitoring step may include using ultrasound or magnetic resonance imaging (MRI) for positioning the resorbable embolic mass at the desired location within the uterine artery. The resorbable embolic mass may be swellable and may be formed of a polymeric material selected from the group consisting of polylactic acid, polyglycolic acid, polyethylene glycol, or copolymers thereof.

2010029, Nov 25, 2010

May 25, 2010

12/787177

Fred H. Burbank - Laguna Niguel CA, US
Paul Lubock - Monarch Beach CA, US
Michael L. Jones - San Clemente CA, US
Richard L. Quick - Mission Viejo CA, US
Frank R. Louw - Carlsbad CA, US
Stephen A. DeSantis - Laguna Niguel CA, US

A61B 6/00

600431

The invention is directed biopsy site markers and methods of marking a biopsy site, so that the location of the biopsy cavity is readily visible by conventional imaging methods, particularly by ultrasonic imaging. The biopsy site markers of the invention have high ultrasound reflectivity, presenting a substantial acoustic signature from a small marker, so as to avoid obscuring diagnostic tissue features in subsequent imaging studies, and can be readily distinguished from biological features. The several disclosed embodiments of the biopsy site marker of the invention have a high contrast of acoustic impedance as placed in a tissue site, so as to efficiently reflect and scatter ultrasonic energy, and preferably include gas-filled internal pores. The markers may have a non-uniform surface contour to enhance the acoustic signature. The markers have a characteristic form which is recognizably artificial during medical imaging. The biopsy site marker may be accurately fixed to the biopsy site so as to resist migration from the biopsy cavity when a placement instrument is withdrawn, and when the marked tissue is subsequently moved or manipulated.

7616979, Nov 10, 2009

Apr 28, 2006

11/413260

Michael L. Jones - San Clemente CA, US
Jill Uyeno - Mission Viejo CA, US
Fred H. Burbank - Laguna Niguel CA, US
Greig E. Altieri - Laguna Beach CA, US

Vascular Control Systems, Inc. - San Juan Capistrano CA

A61B 5/05, A61B 19/00, A61B 17/42, A61M 31/00

600361, 606119, 128898, 604515

The invention provides a devices, methods and systems to measure and record uterine tissue environment components such as pH during the course of uterine artery occlusion. The uterus becomes ischemic due to the occlusion thereof, and its pH drops sharply within minutes of uterine artery occlusion and remains relatively low for a period of time. The return of normal pH is an indicator of return of blood to the ischemic tissue. In use, a catheter with a pH measuring tip is advanced through the patient's vaginal canal and into the patient's uterine cavity until the pH measuring active electrode on the distal end of the catheter contacts or penetrates the uterine fundus. The active electrode detects the pH and a signal representing pH is transmitted to a pH recording and monitoring device which preferably displays the pH. The signal may be transmitted through a conductor or by a radio transmitter. Components other than pH may be monitored such a pCO, and pO.

7354444, Apr 8, 2008

Nov 19, 2002

10/300116

Fred H. Burbank - Laguna Niguel CA, US
Michael L. Jones - San Clemente CA, US
Greig E. Altieri - Laguna Beach CA, US
R. J. Serra - Irvine CA, US

Vascular Control Systems, Inc. - San Juan Capistrano CA

A61B 17/08

606157

Devices, systems and methods for temporarily reducing or abolishing blood flow by occluding blood vessels are provided. A blood vessel-occlusion device embodying features of the invention includes a deployable pressure-applying member with a location sensor, and an applicator. The location sensor is configured to detect a blood vessel, which may be occluded by compression from the pressure-applying member. A pressure-applying member may be released from the applicator, with blood-vessel compression maintained after release. The applicator is configured to engage a guide, such as a tenaculum, to aid in the placement and operation of the applicator. A pressure-applying member may also engage the guide. The invention finds use in, for example, treating uterine disorders and conditions which may be treated by occlusion of the uterine arteries, such as uterine fibroids, dysfunctional uterine bleeding, post-partum hemorrhage, and bleeding associated with caesarian section.

7333844, Feb 19, 2008

Mar 28, 2003

10/402892

Michael L. Jones - San Clemente CA, US
Jill Uyeno - Mission Viejo CA, US
Fred H. Burbank - Laguna Niguel CA, US
Greig E. Altieri - Laguna Beach CA, US

Vascular Control Systems, Inc. - San Juan Capistrano CA

A61B 5/05, A61B 5/00

600361, 600364

The invention provides a devices, methods and systems to measure and record uterine tissue environment components such as pH during the course of uterine artery occlusion. The uterus becomes ischemic due to the occlusion thereof, and its pH drops sharply within minutes of uterine artery occlusion and remains relatively low for a period of time. The return of normal pH is an indicator of return of blood to the ischemic tissue. In use, a catheter with a pH measuring tip is advanced through the patient's vaginal canal and into the patient's uterine cavity until the pH measuring active electrode on the distal end of the catheter contacts or penetrates the uterine fundus. The active electrode detects the pH and a signal representing pH is transmitted to a pH recording and monitoring device which preferably displays the pH. The signal may be transmitted through a conductor or by a radio transmitter. Components other than pH may be monitored such a pCO, and pO.

2008009, Apr 24, 2008

Jul 30, 2007

11/881981

Fred Burbank - Laguna Niguel CA, US
Michael Jones - San Clemente CA, US
Jill Uyeno - Irvine CA, US

A61B 17/42

606119000

The invention is directed to instruments and procedures using such instruments for temporarily reducing or terminating blood flow through a female patient's uterine artery to treat post partum hemorrhage (PPH). The uterine artery is occluded by a clamping device which includes a pair of pivotally connected clamping members, with each of the clamping members having a handle and a clamping element at the distal end of the handle. The clamping elements are inclined with respect to the longitudinal axes of the handles at an included obtuse angle between about 120° and about 170°, preferably between about 130° and 160°. An artery locating sensor is provided on the distal end of at least one of the clamping elements. Preferably, the artery locating sensor is a Doppler ultrasound blood flow sensor. After birth, the clamping device is inserted into the female patient's post partum vaginal canal and advanced therein until one of the clamping elements Is in the patient's uterine cervix and the other clamping element is on the exterior of the uterine cervix. The clamping element on the exterior of the patient's uterine cervix is pressed against the patient's vaginal fornix and the clamping device closed so as to occlude the uterine artery disposed within tissue grasped by the clamping device. The clamping device is locked in the closed configuration and maintained in the condition until the patient's uterus is sufficiently clotted up to ensure termination of the hemorrhaging, typically about 5 minutes to about 7 hours.

7875036, Jan 25, 2011

Oct 24, 2005

11/256768

Fred H. Burbank - Laguna Niguel CA, US
Greig E. Altieri - Laguna Beach CA, US
Michael L. Jones - San Clemente CA, US
Ed Olson - Lake Forest CA, US

Vascular Control Systems, Inc. - San Juan Capistrano CA

A61B 17/42

606119, 606205

A method and device for treating a female patient's uterine disorder by occluding one or both of the patient's uterine artery. The treatment involves occluding one or both of the patient's uterine arteries with an intravaginal device to form a thrombus within the occluded artery or arteries and administering an agent which will prolong the occlusion of the artery or arteries after removal of the occluding device or initiate or accelerate fibroid cell apoptosis (programmed cell death). The intravaginal device has a pair of pivotally connected occluding members, with at least one of the occluding member having a movable occluding element on a distal shaft section of the occluding member.